Pharma Industry, Pharmaceutical Industry Analysis

Tag: pharma industry

Pharmaceutical Value Chain + Market Intelligence

Restoring Normalcy in the Pharmaceutical Value Chain: The Impact of COVID-19 and the Next Step to Success

The COVID-19 pandemic has challenged industries, countries, and governments endlessly over recent months. The spread of the virus has led to a range of issues that impact the foundation and functioning of business operations, GDPs’, and supply chains. All industries are now working towards recovery, and the pharmaceutical industry is attempting to regain control and functionality across the pharmaceutical value chain.

The pharmaceutical value chain includes every component and every process from manufacturer to end-consumer. This includes, but is not limited to, manufacturing, acquiring regulatory approval, import and export, distribution, and retail. The safety regulations, nationwide lockdowns, and transportation disruptions caused by the COVID-19 pandemic are among the biggest factors impacting the pharmaceutical value chain.

Pharmaceutical companies have attempted to develop more streamlined processes and taken various initiatives prior to the COVID-19 pandemic due to the pharmaceutical value chain’s fragmented nature. However, few have succeeded, and the different strategies utilized by companies did not protect the value chain from the hard-hitting impact of the COVID-19 pandemic.

As the pharmaceutical industry focuses its effort towards recovering the pharmaceutical value chain, companies must understand the impact of the pandemic. Therefore, in this article, Infiniti’s market intelligence experts detail the effects of the COVID-19 crisis on the pharmaceutical value chain. Additionally, they discuss the best path to recovery for pharmaceutical companies and highlight the value of market intelligence solutions in this attempt to return to normalcy.

The pharmaceutical industry is on the path to recovery and companies need to strategize for the changing market dynamics and impact of the COVID-19 pandemic. Speak to our industry experts to learn how companies can develop the optimal strategies to face these challenges.

Impact of COVID-19 on the Pharmaceutical Value Chain

As is the case with most industries, there have been innumerable problems posed by the advent of the COVID-19 pandemic in the pharmaceutical value chain. However, three major segments have been severely impacted and will need the most focus and recovery strategies from pharmaceutical companies. The impact of the COVID-19 pandemic on the pharmaceutical value chain can be witnessed in the following three segments:

Pharmaceutical Value Chain + Market Intelligence

APIs and the Dependence on APAC Countries

The pharmaceutical industry’s raw material supply chain was disrupted by the high dependence of pharmaceutical companies on China and India. The two APAC countries source a majority segment of the active pharmaceutical ingredients (APIs), intermediates, and reagents required by pharma companies. Since China was the first infected country, the raw material supply chain was slightly challenged. However, the spread of the virus has impacted India severely and caused a major disruption in the pharmaceutical value chain.

While China is on the path to recovery and is attempting to return to normalcy, India has many obstacles to overcome before it can successfully overcome the impact of the COVID-19 crisis. Restoring operations and recovering from the effects of the pandemic will cost the pharmaceutical value chain a substantial amount of time and effort due to this factor.

Logistics and Distribution Challenges

Countries across the globe have announced nationwide lockdowns and severely limited domestic and international transportation. Although this step was crucial for the containment of this deadly virus, it has led to major logistical challenges across industries. The pharmaceutical value chain has been similarly impacted due to transportation and distribution limitations.

The fragmented nature of the pharmaceutical value chain is one of the reasons the transportation restrictions are impacting the industry severely. The process involves the procurement of various raw materials from different locations in the APAC, North American, and European regions. Additionally, the manufacturing, packaging, distribution, and retailing are conducted in various areas. With the continuous spread of the virus and government restrictions on population movement and transportation, pharmaceutical companies need to evaluate their distribution and logistics strategies to maintain business continuity.

Paused Clinical Trials and the Drug Development Process

A large number of clinical trials worldwide have been suspended, postponed, or halted since the advent of the COVID-19 pandemic. Stakeholders consider this the most impacted segment in the pharma industry. Due to the need for social distancing, the limitations on transport, and the requirements of new hygiene protocols, conducting clinical trials and collecting real-world evidence has been challenging for pharma companies. The halting of clinical trials translates into a delay in the development and time-to-market for various therapies and drugs.

Simultaneously, pharmaceutical companies are struggling to conduct clinical trials to develop a vaccine for the SARS-CoV-2 virus, which causes COVID-19. However, they face challenges finding ideal candidates and carrying out their clinical trials despite the various limitations. Pharma companies and governments are working towards digitalizing the clinical trial process with innovative alternatives such as telemedicine and mailing trial drugs. Efficiently digitalizing, and overcoming the various challenges caused by the COVID-19 pandemic will help companies develop a vaccine and fast-track recovery worldwide.

Understanding the impact of the COVID-19 pandemic on the pharmaceutical value chain is a crucial step for recovery in the pharmaceutical industry. Request more information to gain more in-depth insights into the challenges caused by the pandemic and the next step to recovery.

How can Market Intelligence Solutions help Pharmaceutical Companies Overcome the Impact of COVID-19?

Pharmaceutical companies need a series of solutions to assist them in their attempt to recover from the impact of the COVID-19 pandemic. The pharmaceutical value chain has been significantly disrupted through 2020, and by re-establishing normalcy soon, companies can minimize the long-term implications of the pandemic across the value chain.

Infiniti’s market intelligence solutions can provide companies with insights, guidance, and strategies to help their industry recover as quickly as possible. There are various crucial factors that pharma companies must focus on during the process of recovery, and Infiniti’s market intelligence solutions can help them adapt and recuperate as required. Our market intelligence experts can help pharma companies and the pharmaceutical value chain in the following crucial ways:

  • Companies must improve transparency on the various levels of the supply chain and identify alternative sources for the different raw materials or services that are unavailable. Infiniti’s demand planning solutions enable companies to provide visibility into their operations and supply chains required to make real-time decisions and keep stakeholders informed.
  • There is also an increasing need for companies to analyze their inventory, estimate the available inventory across the value chain, and attempt to continue production and delivery to customers. With Infiniti’s inventory management solutions, companies can try to fulfill customers’ demands despite the disruptions caused by the COVID-19 pandemic.
  • Pharmaceutical companies must also focus on understanding and strategizing for the changing demands of their consumers. With social distancing and new hygiene protocols, consumers have been less likely to renew their prescriptions. Infiniti’s demand management solutions can enable companies to predict, plan, and meet customer demands accurately.

The pharmaceutical industry can successfully recover the pharmaceutical value chain with efficient planning, management, and strategizing. Infiniti’s market intelligence solutions provide companies with the data-driven insights and expert guidance they require to efficiently overcome the impact of the COVID-19 pandemic across the value chain.

Infiniti’s market intelligence solutions can serve as the differentiator between a quick recovery and additional challenges for companies attempting to recover the pharmaceutical value chain. Request a free proposal to enter the post-COVID era as a pharmaceutical industry champion with our expert insights and guidance.

Pharmaceutical Manufacturing Companies + Market Entry

Breaking the Norm: Overcoming Barriers to Entry in the Pharmaceutical Manufacturing Industry

The pharmaceutical manufacturing industry is expected to witness substantial growth in the coming years due to various contributing factors. As lifestyles and habits change, awareness about health and wellness increase, and demand for immediate relief grows, the market is bound to continue growing. Due to advancements in the pharmaceutical and technological fields, there has been an increase in the average life expectancy globally. This directly translates to a larger population of elderly or geriatric individuals, and a continuous need for the pharmaceutical manufacturing industry.

Although awareness about health and wellness is growing, the prevalence of terminal and chronic diseases has grown substantially in recent years, and the need for pharmaceutical drug discovery and development has increased. The pharmaceutical manufacturing industry has also seen a rise in demand due to easy access in the market, with the increased availability of over-the-counter (OTC) medicines. With these market growth drivers, the industry has become a highly competitive space and is attempting to recover from the disruptions caused by the COVID-19 pandemic.

Additionally, pipeline players are now attempting to establish themselves in the recovering industry successfully. However, this industry is considered among the top 10 industries with the highest barriers to entry. Therefore, Infiniti’s market entry experts analyzed the market and identified the most significant barriers to entry in the pharmaceutical manufacturing industry.

With their in-depth analysis, the experts identified four significant barriers to entry, among many others. While identifying and understanding these barriers to entry is important, it is essentially the first step in the process of becoming an industry leader. Infiniti’s market entry analysis helps companies identify, evaluate, and efficiently maneuver the barriers to entry in the pharmaceutical manufacturing industry. In this article, Infiniti’s experts discuss the significant barriers to entry in the pharmaceutical manufacturing industry and highlight the benefits of our market entry analysis.

Entering a market as competitive as the pharmaceutical manufacturing industry is a challenging ordeal. Request a free proposal to successfully break the norm and overcome market entry barriers.

Pharmaceutical Manufacturing Market Entry Barriers

Every industry is plagued with various barriers to entry. Not only is the pharmaceutical manufacturing industry one among these industries, but it also stands among the top 10 most difficult industries to enter. Therefore, our market entry experts identified and evaluated the following four most significant barriers to entry in the pharmaceutical manufacturing industry:

Economies of Scale

The pharmaceutical manufacturing industry requires a well-established distribution network and appropriate infrastructure. This is challenging for new entries into a market and serves as a major barrier to entry. As large pharmaceutical companies dominate the industry, it is difficult for new companies to produce the same drugs at the exact costs and gain market share. Economies of scale play a role in industries such as this one, wherein producers manufacture large quantities of small products. Additionally, brand name recognition plays a crucial role in prescription drugs, particularly drugs with certain effects. Consumers will rarely if ever, choose a brand that is not widely acclaimed or trusted. Therefore, new companies struggle to establish a brand name and gain market share when competing with larger, established pharmaceutical manufacturing companies.

Regulations and Approval

The pharmaceutical manufacturing industry has highly stringent and continually increasing regulations. In the US, the Food and Drug Administration (FDA) takes an average of approximately 21 months to approve a new drug. All pharmaceutical drugs must gain all required regulatory approvals before marketing. Additionally, acquiring FDA approval has proven to be highly challenging, with an extremely low success rate. Obtaining the required approvals is long-drawn and can be extremely expensive for small or new pharmaceutical companies. More often than not, this waiting period allows well-established companies to replicate the product and file a 180-day market exclusivity patent, which in turn provides them with a temporary monopoly. Following this, establishing a monopoly for the new drug can pose a tremendous challenge for the newer company.

Investment Capital

Establishing the required infrastructure, conducting clinical trials, and acquiring all regulatory approvals is extremely expensive. As companies attempt to enter this highly competitive market, they must invest a substantial amount over multiple years. Clinical trials alone require large investments and can still not be approved by the FDA and its parallel administrations across the world. In the US, it can take between 10 to 15 years for a new drug to complete the research and development process, and still face the possibility of not being approved to prescribe for customers. These expenses can be higher depending on the purpose and components of the drug being developed. For new market entries, this translates into high levels of investment, over a prolonged period with no revenue, and the possibility of not gaining approval. Whereas, established pharmaceutical companies continue to earn revenue from previously approved drugs and have the infrastructure in place.

Intellectual Property and Patents

The legal aspect of pharmaceutical manufacturing is agreeably one of the most significant barriers to entry in this market for two reasons. Larger pharmaceutical companies have approved patents that enable them to legally stop new companies from entering the market without establishing a new drug. Additionally, acquiring a patent is a challenging process, and often, patents expire before new companies can acquire the regulatory and FDA approvals that are needed to market and distribute the drug. This enables larger companies to replicate the product and use their distribution and marketing networks to establish a monopoly with the new drug, making it more challenging for new companies to gain revenue and market share.

Request more information to gain more in-depth insights into the impact of investment, regulations, and patents on new companies in the pharmaceutical manufacturing industry.

Pharmaceutical Manufacturing Companies and Market Entry Analysis

Infiniti’s market entry analysis helps new pharmaceutical manufacturing companies identify market entry barriers. It also helps identify and capitalize on appropriate market opportunities and understand the market that they choose to expand into or enter. Infiniti’s market entry experts also help companies with the following:

  • Understanding the needs and expectations of customers, identifying and developing the ideal consumers-centric products that gain the trust of their consumer base
  • Identifying and planning for the most profitable segments of a market, and making optimum use of the company’s resources
  • Evaluating and efficiently maneuvering various barriers to entry, improving profit margins, and extending its business in new, and existing markets

In the pharmaceutical manufacturing industry, Infiniti’s market entry analysis enables companies by providing in-depth insights into the barriers to entry discussed above and other potential obstacles. It also allows them to gain market share in their category and generate substantial savings. Additionally, market entry analysis provides companies with the information they need to develop or adopt strategic initiatives to overcome common challenges, such as regulatory issues or changing market dynamics.

To learn how market entry analysis addresses regulatory and intellectual property challenges in the pharmaceutical manufacturing industry, speak to our experts.

Pharma secondary packaging market

Answering FAQs on Pharmaceutical Logistics

An overview of the global pharmaceutical logistics market

Keeping pharmaceutical products undamaged and therapeutically effective during their journey to the market can often prove to be an arduous and complex task. Once outside the sterile manufacturing and packaging facility, the risk of product contamination during the pharmaceutical logistics process can be high.  The handling of temperature-controlled pharmaceutical products during the pharma logistics process is a complicated business irrespective of the mode of transport and presents unique challenges. Furthermore, the pharmaceutical industry is heavily segmented, resulting in an increased level of M& activity in the sector. The pharmaceutical industry is also experiencing a geographic shift in its major production locations and sales markets. Asia and South America, in particular, are becoming increasingly attractive markets for companies in the sector. But these markets are regarded as the most challenging in terms of supply chain and pharmaceutical logistics operations. As technology and innovation in the pharmaceutical space mature, we can expect advanced and risk-free pharma supply chain and logistics processes in the near future. In this article, Infiniti’s thought leaders answer some key questions relating to pharmaceutical logistics.

Cutting costs and increasing capacity is one of the greater challenges facing the pharmaceutical industry. Looking for ways to achieve this? Request a free proposal from our industry experts.

What are some of the biggest pharmaceutical logistics challenges facing companies currently?

Supply chain visibility is one of the key challenges facing pharmaceutical logistics. This could become a serious challenge especially for companies that intensively deal with regulatory affairs. Pharma manufacturers must overcome this barrier as better supply chain visibility into pharmaceutical logistics as it helps enhance shipment lead times, analyze customer sales projections can drive efficiency benefits, reduce inventories, and improve fulfillment rates. Furthermore, challenges related to increased globalization are presenting suppliers, consumers, and regulatory bodies in the pharmaceutical logistics space with increased risk and uncertainties.

What are some of the key region-specific insights on pharmaceutical logistics?

Pharma logistics are highly mature in Western Europe and the United States. In the future, we can expect least number of supply chain issues from Nordic countries. At present, emerging markets including China and Southeast Asia, the Middle East, South America, and Eastern Europe look highly lucrative for growth in the pharmaceutical industry. As the demand for modern medical treatments and healthcare products rises in these emerging and ‘high-potential’ nations, pharmaceutical companies are moving to unfamiliar territories and cultures and also learning about the accompanying supply chain challenges in these regions. These roadblocks include unstable regulatory environment and underdeveloped logistics infrastructure.

The world of pharmaceutical logistics is a complex, challenging, and ever evolving sphere. But with the right strategies in place you can capitalize on the right opportunities and stay successful. Get in touch with us to know more about how we our solutions can help your business.

 Why is it beneficial for pharma companies to outsource logistics services?

Most of the top benefits of outsourcing pharmaceutical logistics and supply chain include cost benefits. Outsourcing transportation and warehousing help life sciences companies to considerably reduce their overall costs. However, outsourcing does not completely solve supply chain visibility challenges. Moreover, factors including the rise of generics, the fall of the blockbuster model, and a sharp increase in R&D cost are putting companies in the pharmaceutical industry under pressure to bring down costs. Outsourcing logistics is an effective way to reduce the overall costs and also reduce the total time-to-market.

What criteria are most important while choosing a logistics service provider?

Consistency and reliability of services are two key traits that are paramount characteristics to consider while selecting a pharmaceutical logistics service provider. The provider’s industry experience and reputation in terms of safety and security of material handling should also be taken into consideration. Top pharmaceutical companies are already using outsourcing as a strategic part of the company’s overall business strategy especially to establish consistency and efficiency across the international supply chain network. To ensure continued partnership with pharmaceutical companies, logistics service providers must safeguard the confidentiality of the proprietary knowledge, prove its reliability in services, offer continuous improvements, and comply with the regulatory requirements of their clients.

Learn more about our portfolio of services

regenerative medicines

Identifying Key Regenerative Medicine Manufacturing Challenges

Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. We can expect a rapid pace of development in the US regenerative medicine market over the next decade. Some of the key factors fueling demand include the increasing investments in R&D activities and the rising incidence of chronic diseases in the country. Leading vendors have enhanced their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. Furthermore, M&A and strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Nevertheless, the actual delivery of regenerative medicines has proven to be rather challenging with several roadblocks to commercially viable therapies that are capable of catering to unmet clinical needs. In this article, based on a series of discussions with industry analysts at Infiniti Research, we highlight some of the most relevant and pressing manufacturing challenges in regenerative medicine products.

Regenerative medicine

The promise of regenerative medicines requires an innovative look at the complete product lifecycle, including the development of an efficient distribution network. Planning to venture into this space? Request a free proposal for comprehensive insights about the market.

Regenerative medicine manufacturing challenges

Manufacturing expense

Cell therapy manufacturing processes are generally highly expensive. Scaling up from limited laboratory facilities to automated systems for bulk production will largely be based on cost, therefore impeccable financial and time planning become vital. As a first-generation technology, stakeholders we can expect greater stakeholder tolerance for higher pricing, but this will only be for a limited time period. 

Design quality

After collecting sufficient evidence of clinical effectiveness of regenerative medicines, bioreactor technologies are considered for the manufacture of regenerative medicine products. But even minor process changes at this stage will require new validation of the product performance. So, in the case of automation, robots manually reproduce the existing inefficient manual processes due to which the products are often based on obsolete technologies. As a result, the manufacture of regenerative medicines sometimes misses the opportunity to improve their quality by innovating process design.

The personalization and unique requirements of regenerative medicines require manufacturers to provide increased focus on precision and accuracy of processes. Get in touch with an expert from Infiniti research to identify gaps in your existing processes and bridge them with viable business strategies.

Biomaterials challenges

Challenges relating to biomaterials is mostly concerned with their selection than the manufacturing. The trends in material selection will eventually have a major impact on the manufacturing process. As traditional synthetic biodegradable polymers and a few bioactive ceramics that have been manufactured through conventional routes are no longer considered ideal, attention is now being turned toward biomaterials that have more relevant biological properties. But since they have critical nanostructural features, and may involve self-assembly and environmental responsiveness, they may not be compatible with normal top-down manufacturing and therefore could require changes in the production process.

Supply chain challenges

The clinical supply chains required to deliver regenerative medicines therapies are arguably the most complex the industry has seen so far, even more so than for biologic medicine. At present, while billions of dollars are being spent on regenerative medicine research and clinical studies, resources are yet to be allocated to the management and delivery of innovative medical therapies at scale. Furthermore, progress by the pharma industry in coming into compliance with the FDA’s regulations for regenerative medicines has been slow. This makes the process of bringing regenerative medicines at scale to the market even more challenging.  

Learn more about our portfolio of solutions

Pharmaceutical industry

Generating Huge Sales and Realizing Profits of Over 29% for a Pharmaceutical Company Using Market Intelligence Engagement

Pharmaceutical Industry Analysis

The innovations in advanced biologics, rising population, and access to quality healthcare and pharmaceuticals to middle-class people worldwide are driving the growth of the global pharmaceutical industry. However, the fluctuating economy, legal issues, talent shortage, massive flow of generic medicines, and rising competition are expected to impact the growth prospect of the global pharmaceutical industry. Besides, companies in the pharmaceutical industry are facing decreasing return on investment due to price erosion in key markets. As such, companies in the pharmaceutical industry will need to foresee changing market dynamics and look for other markets to sustain growth.

Our market intelligence analysts can help you to assess profitable opportunities in new markets and provide the information you need to expand operations and accelerate growth. Request a FREE proposal today.

Business Challenge

The client is a pharma company based out of the United States.

As Canada is known to be one of the most profitable markets for pharmaceutical companies, the client wanted to expand their business operations to Canada. Before investing a huge sum into their expansion plan, they wanted to determine their growth potential and assess market opportunities in the Canadian pharmaceutical industry. They approached the experts at Infiniti Research to leverage their expertise in offering market intelligence engagement.

Other challenges that the client encountered were:

CaptureGovernment and security: As policies regarding the use of medicines varied in different countries, the client wanted to understand the policies in the Canadian pharmaceutical industry. In addition, they wanted to understand in-detail the procedure for new drug launch in Canada.

Massive flow of generic medicines: Due to the massive flow of less expensive or generic drugs in Canada, the client wanted to identify strategies to cut down on their production costs and gain a competitive edge.

Identifying the right set of customers: Before expanding their operations to Canada, they wanted to identify the profitable customers to focus on to drive sales.

Need for new and effective medicines: The client wanted to analyze competitors’ product offerings and identify drugs gaining popularity in the Canadian pharmaceutical industry. By doing so, they wanted to invest into similar drugs.

By identifying the potential for a new product or service, we help companies to make strategic business decisions and accelerate growth. Contact us today!

Our Approach

The experts at Infiniti Research followed a four-phased approach that involved:

CaptureMarket scanning and monitoring analysis to understand the regulatory changes in the Canadian pharmaceutical industry. This also involved evaluating the market potential for the client’s offerings in Canada and identifying the capital requirement for setting up new production and distribution units.

Technology assessment to spot the next technological breakthrough and identify cost-effective technologies to enhance the client’s operational efficiency.

Customer segmentation analysis to segregate customers into distinct target segments and identify profitable customer groups.

Competitive intelligence solution to analyze the product and service offerings of the top pharma companies in Canada.

Results Obtained

By understanding the current market dynamics and forecasting the potential business opportunities in the Canadian pharmaceutical industry, the client was able to devise a sound market entry plan. Also, by thoroughly understanding the procedures for launching a new product in Canada, they were able to succeed  clinical trials in their initial attempt. In addition, the adoption of cost-effective technologies helped the client to automate their operations and reduce production costs. This further helped them to reduce the costs of their drugs and better compete with generic drug manufacturers.

By identifying the right set of customers, the company in the pharma industry was able to personalize their marketing and sales efforts for them and generate maximum sales. Also, a detailed analysis of their competitors’ offerings helped them to competitively price their products. Within two years of entering the Canadian pharmaceutical industry, the client was able to generate huge sales and realize profits of over 29%.

Capture

Want to know more about our services for pharma companies? Request for more info and our experts will get in touch with you with comprehensive insights.

Trends in pharmaceutical industry

Analyzing the Market Innovations and Trends in Pharmaceutical Industry in the United States | Infiniti Research

Analyzing Trends in Pharmaceutical Industry

Rising healthcare costs and economic uncertainties have put US pharmaceutical companies in a state of turmoil. However, on the brighter side, with biosimilars gaining popularity and new drug pricing and reimbursement approaches, pharmaceutical companies will witness rapid transformations over the coming year. Hence, pharma companies are under the pressure to stay abreast with the latest market innovations and trends in pharmaceutical industry. This is where companies realize the need to leverage market trend analysis solution.

Want to know the latest trends in pharmaceutical industry and keep pace with the market innovations? Our market trend analysis can help. Request a FREE proposal today!

Business Challenge

The client is a Canadian pharmaceutical company. The client was looking to expand their operations to the United States. With rapid transformations happening in the US pharma market, the client wanted to identify the trends in pharmaceutical industry and keep pace with the market innovations. The client, therefore, partnered with Infiniti Research to leverage their expertise in offering market trend analysis solution.

Furthermore, the client wanted to:

Analyze the market potential

By analyzing the trends in pharmaceutical industry and understanding the market innovations, the client wanted to understand the market potential for their product and services in the United States.

Understand technological trends in pharmaceutical industry

With the industry-wide proliferation of cloud technologies and artificial applications (AI) driving pharmaceutical industry growth, the client wanted to analyze all the technological trends in pharmaceutical industry in the United States.

Understand rising demand for biosimilars

With biosimilars gaining popularity in the US pharmaceutical market and providing cost savings for payers and patients, the client wanted to analyze how biosimilars are changing the US pharma market.

Analyze rising drug pricing

With the US government tightening up conditions for drug pricing and related instruments such as rebates and discounts, the client wanted to analyze the trends in pharmaceutical industry related to drug pricing.

Analyzing the latest trends in pharmaceutical industry is becoming vital for pharma companies that are looking to enter a new market or expand their business operations. CONTACT US to know how our market trend analysis can help you understand the latest market innovations and adapt to unexpected market fluctuations.

Solutions Offered

As a part of the trend analysis engagement, the experts at Infiniti Research conducted a thorough US pharmaceutical industry analysis and market sizing analysis. This phase of the trend analysis engagement helped the client to understand the recent market developments and estimate the market potential for their products and services. Also, the client was able to identify the market size of pharmaceutical industry in the US.

The experts also leveraged product research engagement to help the client analyze the complete product development lifecycle, trade-offs, and gain insights on product-specific revenues to boost the value proposition.  Furthermore, the experts analyzed technological trends in pharmaceutical industry and monitored how the client’s major competitors employed the latest technological trends in their business processes.

Furthermore, by leveraging Infiniti’s expertise in conducting industry trend analysis engagement, the experts helped the client to understand how biosimilars are transforming the US pharma industry and analyzed how top US pharma companies are spending on biosimilars.

By leveraging Infiniti’s expertise in offering market opportunity analysis, the experts also helped the client to review potential barriers to market entry and assess markets’ readiness for their product and service offerings.

Results Obtained

With Infiniti’s market trend analysis engagement, the client was able to efficiently analyze the trends in pharmaceutical industry and stay abreast with market innovations. Also, tracking emerging trends in pharmaceutical industry and assessing the regional market developments helped the client to devise a market entry plan to enter the US pharma market. Furthermore, within two years of entering the new market, the client was able to achieve a leading edge in the US pharma market and become one among the top 20 pharma companies in the United States.

Trends in Pharmaceutical Industry

pharma industry trends

Request for more information to learn other benefits of keeping pace with pharma market innovation and analyzing pharmaceutical industry trends.

Market Assessment

Pharma 2020: Key Pharma Industry Trends to Watch Out For

The pharma industry is undergoing a myriad of changes. Therefore, success in today’s pharmaceutical marketplace largely depends on companies’ ability to continually reassess strategic direction, move with agility, and anticipate and adapt to changes. Businesses must not only keep a close watch on the pharma industry trends, but equal emphasis should be given to tackling the upcoming challenges. Some of the key challenges identified during our pharma industry analysis include:

  • Increasing instances of chronic diseases are placing greater pressure on the healthcare budgets
  • Healthcare policy makers are increasing pressure on doctors regarding what to prescribe
  • Growing demand for medicines in emerging economies
  • Regulators are becoming increasingly cautious while approving new and innovative medicines
  • Pharma-economic performance is measured in order to insist on outcome-based pricing

How to overcome these challenges?

All you need a market intelligence solutions provider to guide you with the right solutions for business. Request a free brochure to gain insights into Infiniti’s advanced solutions for the pharma industry.

Pharma industry trends

Despite these challenges, there are several exciting pharma industry trends underway. Infiniti Research’s pharma industry analysis reveals the following trends that companies in this sector must gear up for:

Prevention over treatment

 One of the key pharma industry trends that are expected to go mainstream is the idea of prevention over treatment. Governments across the globe are backing this, especially in the case of chronic diseases. Global pharmaceutical industry analysis suggests that there is an unprecedented amount of supply in prevention supplements and pills around the world. If certain chronic diseases cannot be treated, some of its symptoms and fatal consequences can be prevented through such initiatives.

Reverse innovation

Reverse innovation refers to any innovation which is adopted first by emerging economies and then distributed globally. Pharma industry trends of the future such as reverse innovation provide answers to various challenges faced by companies in the pharma industry including the rising research costs, patent expiration, and consequent revenue declines, and huge costs in bringing a drug to market.

Nanotechnology

Nanotechnology is one of the most notable recent trends in the pharmaceutical industry. Nanotechnology is a scientific, multi-disciplinary effort that involves the creation and utilization of essence systems on a nanometer scale. An important application of this innovation is in the form of ‘Nano-medicine’. Pharma industry experts at Infiniti Research believe nanotechnology to be one of the most impressive pharma industry trends and will unleash several breakthroughs in medicine, diagnosis, and genetic engineering. A key example of an innovative nanomedicine is that of Genexol-PM which is an anti-cancer drug used to fight breast cancer and non-small lung cancer.

Customization or personalized medicine

People around the globe are known to have genetic differences, however, all of us consume similar medicine that has been designed for millions of people. However, this trend is about to change in the near future. Personalized medicine is expected to become one of the most favored pharma industry trends in the future. The drugs will be customized based on the patient’s examination reports and medical records. Though it would take some time for this to become full-fledged in the pharma industry, such trends in the pharma industry will provide enhanced treatment to the patients.  

How can Infiniti’s trend analysis solutions help companies in the pharma industry to keep a close watch on the recent market trends and revamp their strategies to stay at par with top players in the market? Request a proposal to find out.

3D printing

3D printers are under rapid development. The adaptation of this technology in the pharma industry will enable companies in the sector to print the necessary medicines as per requirements. In 2015, the first FDA approved a drug called Spritam was printed. This drug is used to treat epilepsy. This pill was made 3D printing several layers of the powdered drug, binding the layers of powder together, and blowing away the excess powder. The drug easily dissolves when compared to a traditional pill due to its unique structure. This is especially useful for cases where otherwise large, hard-to-swallow pills are prescribed.

Body sensors

Body sensors are breakthrough pharma industry trends that are all set to revamp patient-care and drug prescription. Wearables, integrated body chip, mini robots, and several other types of body sensors can obtain patient information and communicate the same immediately to the healthcare professionals. This can help them make quick and informed decisions regarding the drugs that need to be prescribed to the patient. These systems integrate living human cells with micro-engineering to help researchers and product development teams a new standard for predicting human response with greater precision.

Artificial intelligence

Artificial intelligence and cognitive computers help gather and classify large volumes of data in a matter of seconds. This solves the common problem that the drug discovery process is lengthy and expensive. These advanced technologies will also help pharma companies to run cognitive trials in lesser time. Which means drugs can be delivered to patients much earlier than before.

GET MORE INFO to know more about Infiniti’s solutions for business

Competitor analysis

Top Manufacturing Trends Flourishing in the Pharma Industry

The global economic uncertainties, increasing healthcare costs and expiring patents are putting pharma companies in a state of turmoil. However, on the brighter side, the rapid development of the emerging markets, progress in drug research, the rise in generics production, the availability of high-potency drugs, and innovations in manufacturing trends will sustainably modify the global pharmaceutical landscape. Moreover, the increasing prevalence of chronic diseases and the growing demand for medications, high market growth, new medicines, and therapy forms, changing regulations, and progressing digitization are going to give birth to new manufacturing trends to meet the growing demand.

Manufacturing trends in the pharma industry

Process analytical technology

This initiative sets a legal framework in the USA aiming to motivate pharma companies to improve the production process and achieve consistent quality while reducing waste and costs. In order to comply with this regulation and the changing manufacturing trends, pharma companies need to have systems in place that ensure detailed monitoring of their continuous and batch processes. Process analytical technology is one of the vital manufacturing trends that enables and drives continuous manufacturing. It was identified as one of the most important manufacturing trends in pharma companies along with integrated manufacturing business and automation processes.

banner IR

Digitization and labeling information

Effective tracking, tracing, and labeling is a mandatory proof of authenticity and prevention of drug counterfeiting. Digitization of labeling information has resulted in greater emphasis being placed on collecting, securing, and processing digital data about pharma products.

Low-volume drugs

There are several issues relating to introducing new drugs in the market. This includes manufacturing issues as well, so a review of manufacturing trends in approvals of new molecular entities (NMEs) can provide insight into manufacturing activity. A key trend in NME approvals is the increased share of orphan drugs approved as NMEs. Orphan drugs are defined as drugs that treat diseases which are known to affect 200,000 or fewer people, as defined by the US Food and Drug Administration (FDA). The FDA provides incentives, including market-exclusivity benefits, for developing orphan drugs. Due to a smaller patient population, these drugs are typically produced in lower volumes when compared to primary care drugs.Get More Info

Risk-based manufacturing inspections

The FDA is continuing its plan to use a risk-based selection model for manufacturing inspections in the pharma industry. This forms a part of its strategy to allocate resources more effectively and gain greater parity between inspections of domestic and foreign drug-manufacturing facilities. During September 2018), the FDA published an internal policy that outlines the agency’s risk-based, site-selection model for inspecting foreign drug-manufacturing facilities. The FDA prioritizes inspections of sites regardless of their location with the help of a risk-based site-selection model. This is one of the critical manufacturing trends that pharma companies must watch out for.


Gain more insights into how Infiniti’s solutions can help pharma companies

Contact US

Market Entry Research for a Leading Life Sciences Industry Player

The rising costs and growing complexities associated with developing and bringing products to the market are compelling life sciences industry players to reexamine their business operations. Click To Tweet

Breakthrough developments in drug manufacturing processes have resulted in groundbreaking results that are set to bring in a major transformation in the life sciences industry. However, players will have to tackle major challenges to innovate and evolve in a complex market. Factors such as the need to improve time-to-market and siloed legacy systems are persistent challenges for players in the life sciences industry. Also, the life sciences industry players must possess the ability to quickly gauge the market to meet operational, infrastructure requirements, and devise appropriate market entry startegies.

The Business Challenge

Request Proposal

  • The Client: A life sciences industry major

One of the leading life sciences industry player operating in India wanted to devise an effective strategy to enter the international market. Their decision to enter the overseas market opened distinct new opportunities; thereby, making it difficult for the client to prioritize and gauge the risks in every new market. Hence to develop a precise strategy the client approached Infiniti Research to leverage its expertise in market entry strategy development.


Market Entry Strategy Benefits

The foremost step in launching a product or service deals with the selection of a potential market segment. Though this seems obvious, organizations generally fail to do their due diligence as far as pre-market entry strategies are considered. Moreover, research on the market size, growth prospects, competitive landscape, and technological adoption, it is essential not to disregard other essential factors that affect market growth including- economic landscape, business environment, and consumer groups.  Seemingly similar economies can present stark differences in such indicators leading to sharply divergent market prospects.Get More Info

Hence, a systematic and comprehensive approach to analyzing the factors that affect market potential is a good starting point for any organization and that is what Infiniti’s Market Entry Strategy Solutions are all about. Though the market entry strategy is developed with regards to developing market segments it is equally valid for developed economies.


Summary of Our Market Entry Strategy Engagement

market entry

Contact US


Client’s Journey

To help the life sciences industry player venture into international markets– the experts at Infiniti conducted a detailed market survey to help them gain a better understanding of the potential factors affecting growth in the life sciences industry.

Solution Benefits and the Business Impact

The market entry strategy solution enabled the client to identify the potential beachhead segment to focus and leverage market entry efforts. It also enabled them to select the appropriate business model to maximize profitability.


The Future

The are several reasons why businesses focus on expanding their reach by entering international markets. As far as the life sciences market is considered; lower costs, greater profits, and technological advancements are factors that compel them to enter new market segments. However, prior to undertaking a market entry strategy, it is essential to gain a comprehensive insight into the organizations’ readiness to enter the new segment.

Moreover, the life sciences industry is on the verge of a major industrial transformation which is why leading players are looking at devising an effective market entry strategy to expand their reach. This requires answers to key questions such as- What are the business goals? What measures have been devised to cope with the repercussions of market entry?


A must-read case study for life sciences industry players looking to develop an understanding of the importance of a market entry strategy

Request Proposal


Related posts:

Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice